Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
oleh: Anette S.B. Wolff, Lena Hansen, Marianne Aa. Grytaas, Bergithe E. Oftedal, Lars Breivik, Fan Zhou, Karl Ove Hufthammer, Thea Sjøgren, Jan Stefan Olofsson, Mai Chi Trieu, Anthony Meager, Anders P. Jørgensen, Kari Lima, Kristin Greve-Isdahl Mohn, Nina Langeland, Rebecca Jane Cox, Eystein S. Husebye
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-07-01 |
Deskripsi
Summary: A hallmark of patients with autoimmune polyendocrine syndrome type 1 (APS-1) is serological neutralizing autoantibodies against type 1 interferons (IFN-I). The presence of these antibodies has been associated with severe course of COVID-19. The aims of this study were to investigate SARS-CoV-2 vaccine tolerability and immune responses in a large cohort of patients with APS-1 (N = 33) and how these vaccinated patients coped with subsequent infections. We report that adult patients with APS-1 were able to mount adequate SARS-CoV-2 spike-specific antibody responses after vaccination and observed no signs of decreased tolerability. Compared with age- and gender-matched healthy controls, patients with APS-1 had considerably lower peak antibody responses resembling elderly persons, but antibody decline was more rapid in the elderly. We demonstrate that vaccination protected patients with APS-1 from severe illness when infected with SARS-CoV-2 virus, overriding the systemic danger of IFN-I autoantibodies observed in previous studies.